Avalo Therapeutics, INC Form 4 insider transactions

Jennifer Riley, Chief Strategy Officer of Avalo Therapeutics, Inc., sold 2,655 shares of common stock on August 11, 2026 for $19.59 per share.

Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, Inc., sold 679 shares of common stock on August 10, 2026 for $20.00 per share.

Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, Inc., sold 1,000 shares of common stock on July 27, 2026 for $20.00 per share.

Avalo Therapeutics Chief Medical Officer Mittie Doyle executed trades under a pre-arranged Rule 10b5-1 plan, acquiring and disposing of company stock.

Avalo Therapeutics director Philip Ron M acquired stock options, as disclosed in a recent SEC Form 4 filing.

Avalo Therapeutics Director Kevin Robert Lind acquired 1,105 stock options on June 30, 2026, as detailed in a Form 4 filing.

Avalo Therapeutics, Inc. director Rita Jain reported the acquisition of stock options on June 30, 2026, as detailed in a Form 4 filing.

Mittie Doyle, Chief Medical Officer at Avalo Therapeutics, Inc., reported transactions involving common stock and stock options on June 23, 2026, executed under a Rule 10b5-1 trading plan.

Avalo Therapeutics Director Philip Ron M acquired 40,200 stock options, with vesting over three years, as detailed in a Form 4 filing.

Chief Strategy Officer Jennifer Riley reported the disposition of 588 shares of Avalo Therapeutics common stock to cover tax obligations.

Chief Legal Officer Paul Varki disposed of 1,081 shares of Avalo Therapeutics common stock to cover tax obligations.

Avalo Therapeutics CFO Christopher Sullivan reported a routine disposition of common stock to cover tax obligations.

Chief Medical Officer Mittie Doyle disposed of 1,084 shares of Avalo Therapeutics common stock to cover tax obligations.

Avalo Therapeutics Director Kevin Lind acquired 20,100 stock options with an exercise price of $13.96, vesting fully on June 2, 2026.

Avalo Therapeutics Director Samantha Truex acquired 20,100 stock options with an exercise price of $13.96, vesting fully on June 2, 2026.

Director Gilla Kaplan of Avalo Therapeutics, Inc. acquired stock options for 20,100 shares of common stock.

Avalo Therapeutics Director Aaron Kantoff acquired 20,100 stock options with an exercise price of $13.96, vesting fully on the first anniversary of the grant date.

Avalo Therapeutics Director Michael Heffernan acquired stock options for 29,500 shares of common stock.

Rita Jain, a Director at Avalo Therapeutics, Inc., acquired 20,100 stock options with an exercise price of $13.96, vesting fully on June 2, 2026.

Avalo Therapeutics Chief Strategy Officer Jennifer Riley reported the vesting of performance stock units, converting them into common stock.

Avalo Therapeutics' Chief Financial Officer, Christopher Ryan Sullivan, reported the vesting of performance stock units (PSUs) on May 21, 2026, with shares set to fully vest on August 19, 2028.

Avalo Therapeutics reports that Chief Legal Officer Paul Varki acquired 24,300 shares of common stock through the vesting of performance stock units.

Avalo Therapeutics reports on the vesting of performance stock units for its Chief Medical Officer, Mittie Doyle.

Avalo Therapeutics CEO Garry Arthur acquired 100,200 performance stock units that will vest in August 2028, following the certification of performance goals.

Avalo Therapeutics reports insider transactions involving common stock and stock options, executed under a Rule 10b5-1 trading plan.

Avalo Therapeutics' Chief Financial Officer, Christopher Ryan Sullivan, reported the sale of 18,606 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, reported significant stock transactions on May 5th and 6th, 2026, under a Rule 10b5-1 trading plan.

Avalo Therapeutics Director Mitchell Chan executed a series of stock transactions under a pre-arranged Rule 10b5-1 trading plan.

Avalo Therapeutics CFO Christopher Ryan Sullivan sold 16,915 shares of common stock via a pre-arranged 10b5-1 trading plan.

Avalo Therapeutics, Inc. reports insider transactions involving the acquisition and disposition of common stock and stock options by Chief Medical Officer Mittie Doyle.